Search
for
Sort by
Research 61–90 of 71
- 44391 ICI Therapy Toxicities in Psoriasis
- PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
- No association between low-dose oral minoxidil and tachycardia in a large retrospective cohort study of patients with non-scarring alopecia
- Could Vaccination against COVID-19 Trigger Immune-Mediated Inflammatory Diseases?
- 74126 GLP-1RA Medications and Alopecia: Evaluating Risk Across Diabetic and Non-Diabetic Populations
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- Iron Deficiency in Immune-Mediated Inflammatory Skin Diseases: A Missing Link Between Systemic Inflammation, Immunometabolism, and Disease Burden
- Early androgenetic alopecia as a possible indicator of diabetes mellitus and its link to cardiovascular risks: a cross-sectional study
- Evolving treatment paradigms in dermatology: Insights from emerging and repurposed therapies
- Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
- Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations
- Short-term malignancy risk of JAK inhibitors in severe alopecia areata: a multicenter cohort study
- 0250 Systemic therapy associates with a lower incidence of male infertility among psoriasis patients
- 0441 Systemic autoimmune comorbidity in alopecia totalis and universalis compared with patchy alopecia areata: A retrospective cohort study
- LB923 A matched cohort study evaluating the risk of keloid development in alopecia areata patients
- No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study
- MP74-11 TRENDS IN THE PHARMACOTHERAPY OF NOCTURIA, 2016-2021: ANALYSIS OF A LARGE MULTI-INSTITUTIONAL RESEARCH NETWORK
- The Association Between 5α-Reductase Inhibitors and the Presence of Subsequent Dry Eye Disease in Androgenetic Alopecia: A TriNetX Database Study
- Repositioning Old Drugs for New Battles: The Expanding Role of Drug Repurposing in Cancer, Inflammation, and Metabolic Disease.
- Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study
- Beyond hair loss: Exploring the psychiatric burden of alopecia areata in a large cohort
- Abstracts from the 2024 WDS Forum - virtual option
- Alopecia Areata Associated with Dupilumab: National Database Study
- Directional Association Between Irritable Bowel Syndrome and Dermatological Disease: A Large-Scale Retrospective Study
- Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study
- Neurological post‐acute sequelae of SARS‐CoV‐2 infection
- The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
- No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study
- 76976 Association of Depression with Finasteride Stratified by Dosage and Diagnosis: A Retrospective Cohort Study Using the TriNetX Database
- Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: a global propensity score matched retrospective cohort study